Ovid Therapeutics Inc. (OVID) Financials

OVID

FY2025 annual

Revenue $7.3M +1181.3% YoY

Net Income -$17.4M +34.1% YoY

Free Cash Flow -$38.3M +31.6% YoY

Operating Cash Flow -$38.3M +31.5% YoY

Market Cap $427.7M as of Oct 13, 2026

Price / Sales 270x on $1.6M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 2.0x on $209.9M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OVID SEC filings page.

Ovid Therapeutics Inc. (OVID) reported $7.3M in revenue for fiscal year 2025, up 1181.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OVID FY2025 2026-10-04

Ovid is moving from an earlier revenue spike toward a development-stage model still funded mainly by external capital.

In FY2025, revenue reached $7.3M while operating cash outflow remained $38.3M, showing commercial activity is emerging but not yet funding operations. Development spending remains disproportionate: R&D was $25.6M against that revenue base, while the net loss was $17.4M.

Revenue fell from $208.4M in FY2021 to less than $1M in FY2022. It reached $7.3M by FY2025, but that pattern indicates episodic revenue rather than a consistently scaled commercial base.

The financing-dependent balance sheet received a $75.2M financing inflow in FY2025 alongside 131.9M shares outstanding, indicating replenishment came through external funding rather than operations. Reported cash, equivalents, and investments equaled 28.3 months of the latest annual operating outflow, while the 9.0x current ratio indicates substantial short-term asset coverage.

Financial Health Signals

Financial Health Score 66/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ovid Therapeutics Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Ovid Therapeutics Inc. held $90.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $38.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Ovid Therapeutics Inc. scores 54/100 among other emerging companies.

Dilution

Ovid Therapeutics Inc. had 132M shares outstanding at the end of fiscal year 2025, against 71M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Ovid Therapeutics Inc. scores 24/100 among other emerging companies.

R&D Intensity

Ovid Therapeutics Inc. spent $25.6M on research and development in fiscal year 2025, which was 51.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Ovid Therapeutics Inc. scores 79/100 among other emerging companies.

Revenue Progress

Ovid Therapeutics Inc. reported revenue of $7.3M in fiscal year 2025, against $566K in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Ovid Therapeutics Inc. scores 95/100 among other emerging companies.

Burn Trend

Ovid Therapeutics Inc.'s operations used $38.3M of cash in fiscal year 2025, against $56.0M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Ovid Therapeutics Inc. scores 55/100 among other emerging companies.

Balance Sheet

Ovid Therapeutics Inc.'s cash, cash equivalents and investments came to $90.4M at the end of fiscal year 2025, against $20.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Ovid Therapeutics Inc. scores 88/100 among other emerging companies.

Altman Z-Score Safe

9.32

Ovid Therapeutics Inc. scores 9.32, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($427.7M) relative to total liabilities ($20.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Ovid Therapeutics Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Ovid Therapeutics Inc. reported a net loss of $17.4M while operations used $38.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$733K

YoY-88.3%

Ovid Therapeutics Inc. generated $733K in revenue in Q2 2026. This represents a decrease of 88.3% from the same quarter a year earlier.

EBITDA

-$15.7M

YoY-215.3%

QoQ+12.0%

Ovid Therapeutics Inc.'s EBITDA was -$15.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 215.3% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.

Net Income

-$15.0M

YoY-220.4%

QoQ+11.6%

Ovid Therapeutics Inc. reported -$15.0M in net income in Q2 2026. This represents a decrease of 220.4% from the same quarter a year earlier. Against the prior quarter it is up 11.6%.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$11.3M

YoY-60.1%

QoQ-88.0%

5Y CAGR-44.3%

10Y CAGR-15.7%

Ovid Therapeutics Inc. held $11.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

195M

YoY+174.6%

QoQ+4.6%

5Y CAGR+23.5%

Ovid Therapeutics Inc. had 195M shares outstanding in Q2 2026. This represents an increase of 174.6% from the same quarter a year earlier. Against the prior quarter it is up 4.6%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-7.1%

YoY+1.3pp

QoQ+1.4pp

Ovid Therapeutics Inc.'s ROE was -7.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.4 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$10.0M

YoY+54.0%

QoQ-10.9%

Ovid Therapeutics Inc. invested $10.0M in research and development in Q2 2026. This represents an increase of 54.0% from the same quarter a year earlier. Against the prior quarter it is down 10.9%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

OVID Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OVID quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	$1.6M	$7.3M+1181.3%	$566K+44.4%	$392K-73.9%	$1.5M-99.3%	$208.4M+1551.6%	$12.6M	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.6M	$25.6M-30.4%	$36.8M+28.6%	$28.6M+16.1%	$24.6M-47.6%	$46.9M-26.0%	$63.4M+50.4%	$42.2M+24.8%	$33.8M-32.4%	$50.0M+421.3%	$9.6M+45.0%	$6.6M
SG&A Expenses	$26.3M	$24.1M-6.1%	$25.7M-17.4%	$31.1M-4.2%	$32.4M-12.9%	$37.2M+21.6%	$30.6M+59.1%	$19.3M+0.6%	$19.1M+27.3%	$15.0M+16.1%	$12.9M+96.8%	$6.6M
Operating Income	-$58.4M	-$42.4M+31.4%	-$61.9M-4.4%	-$59.3M-6.7%	-$55.5M-144.7%	$124.2M+252.5%	-$81.4M-32.6%	-$61.4M-16.0%	-$52.9M+18.6%	-$65.0M-188.5%	-$22.5M-70.8%	-$13.2M
EBITDA	N/A	-$42.2M+31.2%	-$61.3M-4.4%	-$58.7M-6.7%	-$55.0M-144.2%	$124.4M+253.4%	-$81.1M-32.7%	-$61.2M-15.8%	-$52.8M+18.7%	-$64.9M-188.8%	-$22.5M-70.6%	-$13.2M
Income Tax	$0	$0	$0	$0	$0-100.0%	$1.3M	$0	$0	$0	$0	N/A	N/A
Net Income	-$34.5M	-$17.4M+34.1%	-$26.4M+49.5%	-$52.3M+3.5%	-$54.2M-144.1%	$122.8M+251.6%	-$81.0M-34.0%	-$60.5M-16.3%	-$52.0M+19.8%	-$64.8M-189.1%	-$22.4M-70.3%	-$13.2M
EPS (Basic)	N/A	N/A	N/A	-$0.74+3.9%	-$0.77-143.3%	$1.78+228.1%	-$1.39	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	N/A	N/A	-$0.74+3.9%	-$0.77-143.8%	$1.76+226.6%	-$1.39	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	N/A	N/A	71M+0.2%	70M+3.5%	68M+16.5%	58M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$733K-88.3%	$0-100.0%	$718K+844.7%	$132K-23.7%	$6.3M+3611.2%	$130K-12.2%	$76K-46.5%	$173K+58.7%
R&D Expenses	$10.0M+54.0%	$11.2M+67.9%	$6.6M+11.0%	$5.9M-25.3%	$6.5M-48.6%	$6.7M-36.0%	$5.9M-44.2%	$7.9M+47.3%
SG&A Expenses	$6.5M+32.7%	$6.7M+10.7%	$6.4M+31.9%	$6.8M+22.4%	$4.9M-39.8%	$6.0M-16.0%	$4.9M-36.7%	$5.5M-18.5%
Operating Income	-$15.7M-209.4%	-$17.8M-42.2%	-$12.3M-14.6%	-$12.5M+5.3%	-$5.1M+75.3%	-$12.6M+27.9%	-$10.7M+41.0%	-$13.2M-10.0%
EBITDA	-$15.7M-215.3%	-$17.8M-43.5%	-$12.3M-16.2%	-$12.5M+4.2%	-$5.0M+75.6%	-$12.4M+28.2%	-$10.6M+41.5%	-$13.1M-9.9%
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$15.0M-220.4%	-$17.0M-66.0%	$9.7M+204.9%	-$12.2M+13.2%	-$4.7M-155.0%	-$10.2M+12.5%	-$9.2M+39.7%	-$14.0M-24.5%
EPS (Basic)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.20-25.0%
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.20-25.0%
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	71M+0.5%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

OVID Balance Sheet

OVID quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$150.9M+63.8%	$92.2M-36.0%	$144.0M-7.2%	$155.3M-20.2%	$194.5M+156.2%	$75.9M-6.1%	$80.8M+69.7%	$47.6M-46.7%	$89.5M+68.7%	$53.0M	N/A
Current Assets	$74.4M+32.9%	$55.9M-49.0%	$109.6M-16.6%	$131.4M-31.0%	$190.5M+154.5%	$74.8M-6.2%	$79.8M+80.3%	$44.3M-50.0%	$88.6M+69.0%	$52.4M	N/A
Cash & Equivalents	$13.2M-50.0%	$26.3M-2.7%	$27.0M-39.7%	$44.9M-76.1%	$187.8M+160.7%	$72.0M+71.9%	$41.9M+14.8%	$36.5M-58.1%	$87.1M+67.7%	$51.9M-25.7%	$69.9M
Short-Term Investments	$56.5M+111.0%	$26.8M-66.0%	$78.8M-6.3%	$84.1M	$0	$0-100.0%	$34.8M+595.3%	$5.0M	$0	$0	$0
Long-Term Investments	$20.8M	$0-100.0%	$17.6M+213.5%	$5.6M+244.5%	$1.6M	$0	$0	$0	$0	$0	$0
Total Liabilities	$20.3M-15.3%	$23.9M-57.4%	$56.2M+144.6%	$23.0M+55.4%	$14.8M-54.2%	$32.3M+198.5%	$10.8M+22.3%	$8.8M+46.9%	$6.0M+61.3%	$3.7M	N/A
Current Liabilities	$8.3M-21.2%	$10.5M-8.3%	$11.5M+64.1%	$7.0M-52.8%	$14.8M-32.9%	$22.1M+109.5%	$10.5M+19.1%	$8.8M+46.9%	$6.0M+61.3%	$3.7M	N/A
Non-Current Liabilities	$12.0M-10.7%	$13.4M-70.0%	$44.8M+179.7%	$16.0M	$0-100.0%	$10.2M+3470.3%	$287K	$0	$0	$0	N/A
Total Equity	$130.7M+91.5%	$68.2M-22.3%	$87.8M-33.6%	$132.3M-26.4%	$179.7M+312.0%	$43.6M-37.7%	$70.0M+80.4%	$38.8M-53.5%	$83.4M+69.3%	$49.3M-27.6%	$68.1M
Retained Earnings	-$321.7M-5.7%	-$304.3M-9.5%	-$277.9M-23.2%	-$225.5M-31.6%	-$171.4M+41.8%	-$294.2M-38.0%	-$213.2M-39.6%	-$152.7M-51.6%	-$100.7M-180.5%	-$35.9M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$232.0M+199.6%	$225.6M+176.3%	$150.9M+63.8%	$63.8M-37.8%	$77.4M-34.4%	$81.7M-38.0%	$92.2M-36.0%	$102.7M-17.9%
Current Assets	$123.6M+193.7%	$160.1M+248.7%	$74.4M+32.9%	$28.8M-56.2%	$42.1M-48.0%	$45.9M-50.7%	$55.9M-49.0%	$65.8M-28.2%
Cash & Equivalents	$11.3M-60.1%	$94.1M+345.0%	$13.2M-50.0%	$20.6M+37.3%	$28.4M-4.3%	$21.1M-31.3%	$26.3M-2.7%	$15.0M-73.9%
Short-Term Investments	$105.9M+966.2%	$61.5M+181.1%	$56.5M+111.0%	$5.0M-89.5%	$9.9M-79.0%	$21.9M-63.3%	$26.8M-66.0%	$47.7M+60.9%
Long-Term Investments	$52.5M+151.3%	$10.1M-51.8%	$20.8M	$20.9M-1.0%	$20.9M-0.7%	$20.9M-5.1%	$0-100.0%	$21.1M+31.0%
Total Liabilities	$22.1M+2.1%	$27.4M+22.3%	$20.3M-15.3%	$19.1M-27.4%	$21.6M-25.9%	$22.4M-58.0%	$23.9M-57.4%	$26.4M+11.1%
Current Liabilities	$10.0M+11.8%	$15.7M+69.2%	$8.3M-21.2%	$6.8M-41.6%	$8.9M-36.8%	$9.3M+4.5%	$10.5M-8.3%	$11.6M+34.2%
Non-Current Liabilities	$12.1M-4.8%	$11.6M-11.2%	$12.0M-10.7%	$12.4M-16.2%	$12.7M-15.6%	$13.1M-70.6%	$13.4M-70.0%	$14.7M-2.3%
Total Equity	$209.9M+276.2%	$198.3M+234.5%	$130.7M+91.5%	$44.7M-41.4%	$55.8M-37.2%	$59.3M-24.3%	$68.2M-22.3%	$76.3M-24.7%
Retained Earnings	-$353.7M-10.8%	-$338.7M-7.7%	-$321.7M-5.7%	-$331.4M-12.3%	-$319.2M-13.6%	-$314.5M-8.6%	-$304.3M-9.5%	-$295.0M-12.4%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

OVID Cash Flow Statement

OVID quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$54.8M	-$38.3M+31.5%	-$56.0M-22.2%	-$45.8M+17.1%	-$55.2M-146.6%	$118.6M+329.9%	-$51.6M-1.0%	-$51.1M-12.1%	-$45.6M-44.8%	-$31.5M-76.8%	-$17.8M-224.5%	-$5.5M
Depreciation & Amortization	N/A	$273K-55.5%	$613K+7.9%	$568K+10.8%	$513K+116.2%	$237K-22.7%	$307K+20.3%	$255K+79.9%	$142K+76.5%	$80K+42.1%	$57K+379.8%	$12K
Stock-Based Compensation	N/A	$4.8M-23.4%	$6.3M-13.9%	$7.3M+11.1%	$6.6M+29.7%	$5.1M-32.8%	$7.5M+44.6%	$5.2M-26.3%	$7.1M+10.4%	$6.4M+75.7%	$3.6M+149.9%	$1.5M
Capital Expenditures	N/A	$0-100.0%	$71K+77.5%	$40K-96.7%	$1.2M+565.4%	$184K+44.6%	$127K+122.6%	$57K+68.7%	$34K-12.9%	$39K+28.1%	$30K-5.4%	$32K
Free Cash Flow	N/A	-$38.3M+31.6%	-$56.0M-22.3%	-$45.8M+18.8%	-$56.5M-147.7%	$118.4M+329.0%	-$51.7M-1.1%	-$51.1M-12.2%	-$45.6M-44.7%	-$31.5M-76.7%	-$17.8M-223.2%	-$5.5M
Investing Cash Flow	-$147.8M	-$49.9M-191.3%	$54.6M+2215.2%	-$2.6M+97.1%	-$87.9M-4725.0%	-$1.8M-105.3%	$34.6M+215.3%	-$30.0M-460.1%	-$5.4M-11218.8%	-$47K	N/A	N/A
Financing Cash Flow	$185.8M	$75.2M+11991.2%	$622K-98.0%	$30.5M+16802.1%	$181K-80.0%	$904K-98.1%	$47.1M-45.6%	$86.5M+30143.7%	$286K-99.6%	$66.7M	N/A	N/A
Dividends Paid	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$17.6M-268.5%	-$13.9M-35.2%	-$10.4M-4.0%	-$12.9M+14.2%	-$4.8M+66.5%	-$10.3M+38.4%	-$10.0M+16.0%	-$15.0M-49.3%
Depreciation & Amortization	$16K-83.8%	$35K-75.2%	$17K-89.4%	$17K-89.9%	$99K-33.1%	$141K+3.7%	$160K+14.3%	$169K+16.6%
Stock-Based Compensation	$1.4M+17.4%	$1.0M-18.5%	N/A	$1.1M-15.3%	$1.2M-29.9%	$1.3M-34.8%	N/A	$1.3M-19.8%
Capital Expenditures	N/A	N/A	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$22K+69.2%	-$4K-33.3%
Free Cash Flow	N/A	N/A	-$10.4M-3.8%	-$12.9M+14.2%	-$4.8M+66.6%	-$10.3M+38.5%	-$10.0M+15.9%	-$15.0M-49.2%
Investing Cash Flow	-$86.7M-819.7%	$6.0M+16.6%	-$72.1M-438.4%	$5.1M+1630.5%	$12.1M-6.0%	$5.1M-74.7%	$21.3M+143.9%	$292K+106.7%
Financing Cash Flow	$21.6M	$89.0M+684376.9%	$75.2M	$15K-60.5%	$0-100.0%	$13K-94.3%	$0-100.0%	$38K-83.0%
Dividends Paid	$0	$0	$0	$0	$0	$0	$0	$0

Not reported in any period shown, so not listed: Share Buybacks.

OVID Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

OVID quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Margin	-585.2%	-10933.8%	-15122.7%	-3696.4%	59.6%	-645.4%	N/A	N/A	N/A	N/A	N/A
Net Margin	-239.9%	-4664.3%	-13341.8%	-3604.7%	59.0%	-642.3%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-13.3%+25.4pp	-38.7%+20.9pp	-59.6%-18.6pp	-40.9%-109.3pp	68.3%+254.1pp	-185.7%-99.4pp	-86.3%+47.6pp	-133.9%-56.3pp	-77.7%-32.2pp	-45.5%-26.1pp	-19.3%
Return on Assets	-11.5%+17.1pp	-28.6%+7.7pp	-36.3%-1.4pp	-34.9%-98.0pp	63.1%+169.9pp	-106.7%-31.9pp	-74.8%+34.3pp	-109.1%-36.6pp	-72.4%-30.2pp	-42.3%	N/A
Current Ratio	8.97+3.7x	5.32-4.2x	9.55-9.2x	18.79+5.9x	12.87+9.5x	3.39-4.2x	7.58+2.6x	5.01-9.7x	14.71+0.7x	14.04	N/A
Debt-to-Equity	0.16-0.2x	0.35-0.3x	0.64+0.5x	0.17+0.1x	0.08-0.7x	0.74+0.6x	0.15-0.1x	0.23+0.2x	0.070.0x	0.08	N/A
Asset Turnover	0.050.0x	0.010.0x	0.000.0x	0.01-1.1x	1.07+0.9x	0.17	N/A	N/A	N/A	N/A	N/A
FCF Margin	-528.6%	-9898.8%	-11689.0%	-3756.6%	56.8%	-409.8%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	-2141.6%	N/A	-1712.1%	-9487.1%	-80.9%	-9653.9%	-14111.8%	-7645.1%
Net Margin	-2047.6%	N/A	1347.8%	-9210.6%	-74.7%	-7873.1%	-12132.9%	-8096.0%
Return on Equity	-7.1%+1.3pp	-8.6%+8.7pp	7.4%+20.9pp	-27.2%-8.8pp	-8.4%-18.0pp	-17.3%-2.3pp	-13.5%+3.9pp	-18.4%-7.3pp
Return on Assets	-6.5%-0.4pp	-7.5%+5.0pp	6.4%+16.4pp	-19.0%-5.4pp	-6.0%-13.3pp	-12.5%-3.6pp	-10.0%+0.6pp	-13.6%-4.6pp
Current Ratio	12.39+7.7x	10.17+5.2x	8.97+3.7x	4.24-1.4x	4.72-1.0x	4.93-5.5x	5.32-4.2x	5.66-4.9x
Debt-to-Equity	0.11-0.3x	0.14-0.2x	0.16-0.2x	0.43+0.1x	0.39+0.1x	0.38-0.3x	0.35-0.3x	0.35+0.1x
Asset Turnover	0.00-0.1x	0.000.0x	0.000.0x	0.000.0x	0.08+0.1x	0.000.0x	0.000.0x	0.000.0x
FCF Margin	N/A	N/A	-1449.6%	-9751.5%	-76.1%	-7907.7%	-13197.4%	-8676.9%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Ovid Therapeutics Inc. OVID	FY2025	$7.3M	-$17.4M	N/A	$427.7M	66/100
XBiotech Inc XBIT	FY2025	N/A	-$45.5M	N/A	$69.8M	—
Atara Biotherapeutics, Inc ATRA	FY2025	$120.8M	$32.7M	27.1%	$94.2M	63/100
Quince Therapeutics, Inc. QNCX	FY2025	N/A	-$84.0M	N/A	$32.3M	—
Entera Bio Ltd. ENTX	FY2025	$42K	-$11.4M	N/A	$460.7M	—
Opus Genetics, Inc. IRD	FY2025	$14.2M	-$49.6M	N/A	$386.0M	38/100

Where Ovid Therapeutics Inc. Ranks

Frequently Asked Questions

What is Ovid Therapeutics Inc.'s annual revenue?

Ovid Therapeutics Inc. (OVID) reported $7.3M in total revenue for fiscal year 2025. This represents a 1181.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ovid Therapeutics Inc.'s revenue growing?

Ovid Therapeutics Inc. (OVID) revenue grew by 1181.3% year-over-year, from $566K to $7.3M in fiscal year 2025.

Is Ovid Therapeutics Inc. profitable?

No, Ovid Therapeutics Inc. (OVID) reported a net income of -$17.4M in fiscal year 2025.

What is Ovid Therapeutics Inc.'s EBITDA?

Ovid Therapeutics Inc. (OVID) had EBITDA of -$42.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ovid Therapeutics Inc.'s return on equity (ROE)?

Ovid Therapeutics Inc. (OVID) has a return on equity of -13.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Ovid Therapeutics Inc.'s free cash flow?

Ovid Therapeutics Inc. (OVID) recorded an outflow of $38.3M in free cash flow during fiscal year 2025. This represents a 31.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ovid Therapeutics Inc.'s operating cash flow?

Ovid Therapeutics Inc. (OVID) recorded an outflow of $38.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Ovid Therapeutics Inc.'s total assets?

Ovid Therapeutics Inc. (OVID) had $150.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Ovid Therapeutics Inc.'s capital expenditures?

Ovid Therapeutics Inc. (OVID) reported no capital expenditure during fiscal year 2025.

How much does Ovid Therapeutics Inc. spend on research and development?

Ovid Therapeutics Inc. (OVID) invested $25.6M in research and development during fiscal year 2025.

How many shares does Ovid Therapeutics Inc. have outstanding?

Ovid Therapeutics Inc. (OVID) had 132M shares outstanding as of fiscal year 2025.

What is Ovid Therapeutics Inc.'s current ratio?

Ovid Therapeutics Inc. (OVID) had a current ratio of 8.97 as of fiscal year 2025, which is generally considered healthy.

What is Ovid Therapeutics Inc.'s debt-to-equity ratio?

Ovid Therapeutics Inc. (OVID) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ovid Therapeutics Inc.'s return on assets (ROA)?

Ovid Therapeutics Inc. (OVID) had a return on assets of -11.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Ovid Therapeutics Inc.'s P/E ratio?

Ovid Therapeutics Inc. (OVID) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $427.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Ovid Therapeutics Inc.'s price-to-sales ratio?

Ovid Therapeutics Inc. (OVID) trades at 270x sales, its market capitalization divided by revenue of $1.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $427.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Ovid Therapeutics Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Ovid Therapeutics Inc. (OVID) held $90.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $38.3M over that year. Dividing the one by the other, the reported balance equals about 28 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Ovid Therapeutics Inc.'s Altman Z-Score?

Ovid Therapeutics Inc. (OVID) has an Altman Z-Score of 9.32, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Ovid Therapeutics Inc.'s Piotroski F-Score?

Ovid Therapeutics Inc. (OVID) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ovid Therapeutics Inc.'s earnings high quality?

Ovid Therapeutics Inc. (OVID) reported a net loss of $17.4M while operations used $38.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Ovid Therapeutics Inc.?

Ovid Therapeutics Inc. (OVID) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.